Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK835726 single-dose crossover study in seasonal allergic rhinitis
2008-004092-22Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK835726 in seasonal allergic rhinitis (SAR) (5 arms), sponsored by GSK. Primary endpoint: Effect of GSK835726 on nasal symptoms after allergen challenge. Started Jan 2009; status: completed.
02
Drugs
GSK835726
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2008-004092-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004092-22.